Assessing the comparative effectiveness and harms of various treatments for localized prostate cancer treatments is difficult because of limitations in evidence, according to a study to be published in the March 18, 2008, edition of the Annals of Internal Medicine.
Assessing the comparative effectiveness and harms of various treatments for localized prostate cancer treatments is difficult because of limitations in evidence, according to a study to be published in the March 18, 2008, edition of the Annals of Internal Medicine.
Timothy Wilt, MD, of the University of Minnesota School of Medicine, Minneapolis, and colleagues, analyzed 18 randomized, controlled trials and 473 observational studies and discovered the following:
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
Experts develop guide on online tools to reduce costs of urologic drugs
April 22nd 2024"At a time when patients are increasingly concerned about prescription drugs, this information will provide a useful starting point for making essential medications as affordable as possible," says Ruchika Talwar, MD.